We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Despite Mylan’s efforts to quell criticism, U.S. lawmakers continue to press the company and the FDA for greater transparency on the cost of the company’s EpiPen epinephrine auto-injector. Read More
Applications for generics of Johnson & Johnson’s Risperdal should contain characterization data on the reference product and the copycat version, the FDA says. Read More
In response to criticism surrounding the price of its EpiPen, Mylan plans to sell a generic version of its allergy treatment for half the price. Read More